Prediction of survival benefit when deciding between chemotherapy and best supportive therapy in elderly patients with advanced gastric cancer: A retrospective cohort study

Sugimoto,Aya; Nishida,Tsutomu; Osugi,Naoto; Takahashi,Kei; Mukai,Kaori; Nakamatsu,Dai; Matsubara,Tokuhiro; Hayashi,Shiro; Yamamoto,Masashi; Nakajima,Sachiko; Fukui,Koji; Inada,Masami

doi:10.3892/mco.2018.1772

Prediction of survival benefit when deciding between chemotherapy and best supportive therapy in elderly patients with advanced gastric cancer: A retrospective cohort study

Authors:
- Aya Sugimoto
- Tsutomu Nishida
- Naoto Osugi
- Kei Takahashi
- Kaori Mukai
- Dai Nakamatsu
- Tokuhiro Matsubara
- Shiro Hayashi
- Masashi Yamamoto
- Sachiko Nakajima
- Koji Fukui
- Masami Inada
View Affiliations

Affiliations: Department of Gastroenterology, Toyonaka Municipal Hospital, Toyonaka, Osaka 560‑8565, Japan
Published online on: November 19, 2018 https://doi.org/10.3892/mco.2018.1772
Pages: 83-91
Copyright: © Sugimoto et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

It remains unclear whether elderly patients (EPs) with advanced gastric cancer (AGC) benefit from chemotherapy. The aim of the present study was to examine the prognostic factors for EPs with AGC in order to generate a prognosis‑predicting scoring system. This single‑center retrospective study examined consecutive patients with AGC between April 2012 and July 2017. Risk factors for survival in EPs aged ≥75 years were identified using a Cox proportional hazards model, and a prognostic scoring system was generated and retrospectively evaluated to determine its usefulness for predicting patient prognosis. A total of 61 patients were enrolled as EPs (mean age, 81 years) and compared with 80 non‑EPs (mean age, 66 years). The median survival time (MST) was significantly longer for non‑EPs compared with that for EPs (3.8 vs. 10.1 months, respectively; P=0.0447). Among the EPs, 29 (48%) received chemotherapy and 32 received best supportive care (BSC). A total of 68 non‑EPs (85%) received chemotherapy and 12 non‑EPs received BSC. Among EPs with AGC, age‑adjusted multivariate analysis revealed that performance status (PS), neutrophil/lymphocyte ratio (NLR)<4, intestinal‑type histology and chemotherapy were significant prognostic factors. To predict EPs too frail for chemotherapy prior to treatment, one point was assigned for a PS of 1, diffuse‑type histology and NLR≥4, whereas 2 points were assigned for PS≥2, and the point totals for each patient were calculated. A cut‑off point of 2 had the best P‑value by the log‑rank test and was used to divide the patients into low‑risk (LoR: Score 0‑1) and high‑risk (HiR: Score 2‑4) groups. The MST of the LoR and HiR groups was 23.6 and 3.6 months, respectively (P<0.001). As regards treatment strategies and risk groups, the LoR chemotherapy group had the best prognosis (P=0.0010), and LoR EPs who were administered chemotherapy had a longer MST (30.3 months) compared with EPs who received BSC (8.7 months). In conclusion, scoring systems using PS, histology and NLR may be useful when considering chemotherapy in EPs with AGC.

View Figures

View References

1	International Agency for Research on Cancer: Estimated number of incident cases, both sexes, worldwide (top 10 cancer sites) in 2012. 2012.http://gco.iarc.fr/today/online-analysis-multi-bars?mode=cancer&mode_population=continents&population=900&sex=0&cancer=29&type=0&statistic=0&prevalence=0&color_palette=defaultSeptember 11–2018
2	International Agency for Research on Cancer: Estimated number of deaths, both sexes, worldwide (top 10 cancer sites) in 2012. 2012.http://gco.iarc.fr/today/online-analysis-multi-bars?mode=cancer&mode_population=continents&population=900&sex=0&cancer=29&type=1&statistic=0&prevalence=0&color_palette=defaultSeptember 11–2018
3	Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J and Fleig WE: Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 3:CD0040642010.
4	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
5	Szkandera J, Stotz M, Absenger G, Stojakovic T, Samonigg H, Kornprat P, Schaberl-Moser R, Alzoughbi W, Lackner C, Ress AL, et al: Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients. Br J Cancer. 110:183–188. 2014. View Article : Google Scholar : PubMed/NCBI
6	McMillan DC, Forrest LM, O'Gorman P, Angerson WJ and McArdle CS: Performance status of male and female advanced cancer patients is independently predicted by mid-upper arm circumference measurement. Nutr Cancer. 42:191–193. 2002. View Article : Google Scholar : PubMed/NCBI
7	Wei Y, Jiang YZ and Qian WH: Prognostic role of NLR in urinary cancers: A meta-analysis. PLoS One. 9:e920792014. View Article : Google Scholar : PubMed/NCBI
8	Imrie CW: Host systemic inflammatory response influences outcome in pancreatic cancer. Pancreatology. 15:327–330. 2015. View Article : Google Scholar : PubMed/NCBI
9	Charlson ME, Pompei P, Ales KL and MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 40:373–383. 1987. View Article : Google Scholar : PubMed/NCBI
10	Sano T and Aiko T: New Japanese classifications and treatment guidelines for gastric cancer: Revision concepts and major revised points. Gastric Cancer. 14:97–100. 2011. View Article : Google Scholar : PubMed/NCBI
11	Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, et al: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol. 9:215–221. 2008. View Article : Google Scholar : PubMed/NCBI
12	Aapro MS, Köhne CH, Cohen HJ and Extermann M: Never too old? Age should not be a barrier to enrollment in cancer clinical trials. Oncologist. 10:198–204. 2005. View Article : Google Scholar : PubMed/NCBI
13	Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr and Albain KS: Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 341:2061–2067. 1999. View Article : Google Scholar : PubMed/NCBI
14	Monfardini S, Sorio R, Boes GH, Kaye S and Serraino D: Entry and evaluation of elderly patients in European Organization for Research and Treatment of Cancer (EORTC) new-drug-development studies. Cancer. 76:333–338. 1995. View Article : Google Scholar : PubMed/NCBI
15	Giovanazzi-Bannon S, Rademaker A, Lai G and Benson AB III: Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: An Illinois Cancer Center study. J Clin Oncol. 12:2447–2452. 1994. View Article : Google Scholar : PubMed/NCBI
16	Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A, Lang I and Falcon S: Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: The FLAGS trial. J Clin Oncol. 28:1547–1553. 2010. View Article : Google Scholar : PubMed/NCBI
17	Koizumi W, Akiya T, Sato A, Sakuyama T, Sasaki E, Tomidokoro T, Hamada T, Fujimori M, Kikuchi Y, Shimada K, et al: Phase II study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer: The Tokyo Cooperative Oncology Group study. Cancer Chemother Pharmacol. 65:1093–1099. 2010. View Article : Google Scholar : PubMed/NCBI
18	Imamura H, Kishimoto T, Takiuchi H, Kimura Y, Morimoto T, Imano M, Iijima S, Yamashita K, Maruyama K, Otsuji T, et al: Phase II study of S-1 monotherapy in patients over 75 years of age with advanced gastric cancer (OGSG0404). J Chemother. 26:57–61. 2014. View Article : Google Scholar : PubMed/NCBI
19	Zhang X, Zhang W and Feng LJ: Prognostic significance of neutrophil lymphocyte ratio in patients with gastric cancer: A meta-analysis. PLoS One. 9:e1119062014. View Article : Google Scholar : PubMed/NCBI
20	Hwang JE, Kim HN, Kim DE, Choi HJ, Jung SH, Shim HJ, Bae WK, Hwang EC, Cho SH and Chung IJ: Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer. BMC Cancer. 11:4892011. View Article : Google Scholar : PubMed/NCBI
21	Namikawa T, Munekage E, Munekage M, Maeda H, Yatabe T, Kitagawa H, Kobayashi M and Hanazaki K: Evaluation of systemic inflammatory response biomarkers in patients receiving chemotherapy for unresectable and recurrent advanced gastric cancer. Oncology. 90:321–326. 2016. View Article : Google Scholar : PubMed/NCBI
22	Arai T, Esaki Y, Inoshita N, Sawabe M, Kasahara I, Kuroiwa K, Honma N and Takubo K: Pathologic characteristics of gastric cancer in the elderly: A retrospective study of 994 surgical patients. Gastric Cancer. 7:154–159. 2004. View Article : Google Scholar : PubMed/NCBI
23	Wang JY, Hsieh JS, Huang CJ, Huang YS and Huang TJ: Clinicopathologic study of advanced gastric cancer without serosal invasion in young and old patients. J Surg Oncol. 63:36–40. 1996. View Article : Google Scholar : PubMed/NCBI
24	Hashimoto H, Esaki Y, Kino K, Takahashi T and Takubo K: Gastric cancer in the elderly - relationship between macroscopic appearance and histological type in autopsy specimens. Nippon Ronen Igakkai Zasshi. 34:499–505. 1997.(In Japanese). View Article : Google Scholar : PubMed/NCBI
25	Mizoe A, Tanaka K, Ura K, Izawa K, Tsunoda T and Kanematsu T: Long term prognosis according to histological type of gastric cancer. J Jpn Pract Surg Soc. 54:1732–1737. 1993.(In Japanese).
26	Forrest LM, McMillan DC, McArdle CS, Angerson WJ and Dunlop DJ: Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 89:1028–1030. 2003. View Article : Google Scholar : PubMed/NCBI
27	Osugi J, Muto S, Matsumura Y, Higuchi M, Suzuki H and Gotoh M: Prognostic impact of the high-sensitivity modified Glasgow prognostic score in patients with resectable non-small cell lung cancer. J Cancer Res Ther. 12:945–951. 2016. View Article : Google Scholar : PubMed/NCBI
28	Decoster L, Van Puyvelde K, Mohile S, Wedding U, Basso U, Colloca G, Rostoft S, Overcash J, Wildiers H, Steer C, et al: Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: An update on SIOG recommendations. Ann Oncol. 26:288–300. 2015. View Article : Google Scholar : PubMed/NCBI